Speaker illustration

Professor Shizuya Yamashita

Rinku General Medical Center, Izumisano (Japan)

Pemafibrate has a novel mechanism of action to lower LDL-C and ApoB in patients with higher LDL-C levels: Insights from a phase 2 exploratory clinical pharmacology crossover study

Event: ESC Congress 2023

Topic: Lipid-Lowering Agents

Session: Hypertriglyceridemia treatment: CEPT, icosapent ethyl, and fibrates


ESC 365 is supported by